Metastatic disease that is not amenable to curative surgery or radiation
3. Part B, must have a histologically or cytologically documented diagnosis of esophageal or gastric carcinoma, nasopharyngeal carcinoma (NPC), endometrial cancer, soft tissue sarcoma, or other orphan tumor who have received at least one line of standard systemic therapy for their respective tumor type in the metastatic setting with progressive locally advanced or metastatic disease that is not amenable to definitive local therapy with curative intent;
Histological diagnosis of locally advanced (primary or recurrent) or metastatic solid tumor that is not amenable for treatment with curative intent as follows:
Has metastatic disease defined as disseminated disease distant to the initial/primary site of diagnosis, and/or must have locally recurrent disease that has been previously treated (with either surgery, radiotherapy, or systemic therapy), and is not amenable to either curative surgery, radiotherapy, or concurrent chemoradiotherapy treatment.
Participant has histological confirmation of a locally advanced or metastatic solid tumor of a type associated with Prolactin Receptor (PRLR) expression that has progressed on prior treatment, is not amenable to treatment with curative intent, and has no other therapy options known to provide clinical benefit or the subject is ineligible for such therapies.
Participants must have disease that is not amenable to curative resection
Advanced disease is defined as metastatic disease or locally advanced disease that is not amenable to surgery or radiotherapy with curative intent
All disease must be amenable to embolization in one or two procedures
Has histologically or cytologically confirmed triple negative breast carcinoma that is either metastatic (stage IV of the TNM classification) or locally recurrent and not amenable to local curative treatment.
Locally advanced disease must not be amenable to resection with curative intent
Patients must have disease that is not amenable to potentially curative resection; either primary in-situ (or locally-recurrent) tumor must be present and, in the opinion of radiation oncology, be amenable to radiation therapy as planned in the protocol or an extrapancreatic lesion which in the opinion of the radiation oncologist is amenable to radiation; each case will be discussed at gastrointestinal (GI) tumor board with multidisciplinary team
Part B7: Must have a diagnosis of HR+ and HER2- breast cancer; have locoregionally recurrent disease not amenable to resection or radiation therapy with curative intent or metastatic disease; no previous treatment or currently receiving 1 of the following treatments for locoregionally recurrent or metastatic breast cancer (chemotherapy, endocrine therapy, CDK4/6 inhibitor, and PI3K and/or mTOR inhibitor)
Adenocarcinoma of the stomach or GEJ with inoperable locally advanced or recurrent and/or metastatic disease, not amenable to curative therapy
Diagnosis of advanced or metastatic cancer not amenable to curative therapy
Has a pathologically documented unresectable advanced NSCLC disease not amenable to curative therapy
Patients must have recurrent or metastatic HNSCC stage III/IV that is not amenable to local therapy with curative intent (surgery or radiation therapy with or without chemotherapy)
Has locally advanced or metastatic NSCLC, not amenable to curative surgery or radiation.
Patients with stage IV metastatic cancer and/or cancer that is not amenable to surgery (i.e. must be curative intent; locally advanced is acceptable if completely resected)
Male or female advanced (locoregionally recurrent or metastatic) breast cancer not amenable to curative therapy.
Patients must have advanced disease that is not amenable to transplant or resection
Histologically or cytologically confirmed adenocarcinoma of the breast with evidence of metastatic disease (stage IV) or locally advanced disease, not amenable to surgery or radiation with curative intent
Unresectable or metastatic breast cancer; locally recurrent disease must not be amenable to any local treatment with curative intent; metastatic disease must be demonstrated either radiographically or histologically
Histologically or cytologically proven diagnosis of breast cancer with evidence of metastatic or locally advanced disease, not amenable to resection or radiation therapy with curative intent
Advanced disease (Masaoka staging) not amenable to curative treatment
Locally advanced or metastatic disease not amenable to surgery
Pathologically confirmed advanced pancreatic cancer defined as non-operable in a curative intent, locally recurrent, or metastatic disease
Metastatic disease not amenable to surgical resection with curative intent
Barcelona Clinic Liver Cancer (BCLC) Stage B or C disease not amenable to or progressing after loco-regional therapy and not amenable to a curative treatment approach
Women with histologically or cytologically confirmed breast cancer with evidence of metastatic or locally advanced disease not amenable to any local therapy with curative intent.
Adult men and women (? 18 years of age) with histologically confirmed diagnosis of metastatic and/or advanced solid tumors not amenable to curative treatment by surgery.
Histological diagnosis of locally advanced (primary or recurrent) or metastatic solid tumors that are not amenable for treatment with curative intent
Confirmed diagnosis of ER-positive, HER2-negative advanced breast cancer, not amenable to curative therapy
Pathologically confirmed diagnosis of stage IIIB/IV recurrent squamous cell NSCLC defined as not amenable to local curative therapy (surgery, radiation, or chemoradiation), and refractory to systemic therapy OR Pathologically or radiologically (fulfilling non-invasive criteria) confirmed diagnosis of HCC not amenable to resection (partial hepatectomy or liver transplantation) or local therapy with curative intent (e.g. radiofrequency ablation) and must not be a liver transplant candidate as defined according to Milan criteria
Have advanced (not amenable to potentially curative surgery) or metastatic RCC
Disease that is amenable to serial biopsies
Advanced (not amenable to curative surgery or radiation therapy) or metastatic (AJCC Stage IV) RCC
Metastatic disease or locally-advanced disease not amenable to curative intent treatment
Males or females with advanced (locoregionally recurrent or metatstatic) breast cancer not amenable to curative therapy
Phase I: Patients must have histologically confirmed breast cancer (metastatic breast cancer [MBC]) that is human epidermal growth factor receptor 2 (HER2/neu) negative (as determined by local pathology or reference laboratory), and have disease that is metastatic (stage IV [TxNxM1]) or locally advanced and not amenable to potentially curative surgical resection (eg, clinical stage IIIB-C)
Locally advanced breast cancer that is not amenable to curative radiation or surgical cure and/or metastatic disease appropriate for systemic single cytotoxic chemotherapy
The subject has disease that is not amenable to a curative treatment approach.
The tumor is unresectable and not amenable to curative therapy.
Locally advanced or metastatic disease; locally advanced disease must not be amenable to resection with curative intent.
Adult women (? 18 years of age) with metastatic or recurrent locally advanced BC, not amenable to curative treatment by surgery or radiotherapy, with objective evidence of disease progression.
Participant must have metastatic or advanced NSCLC (Stage IIIB or IV) that is not amenable to surgical resection or radiation or chemoradiation with curative intent at time of study screening.
Histologically or cytologically proven diagnosis of adenocarcinoma of the breast with evidence of either locally recurrent disease not amenable to resection or radiation therapy with curative intent, or metastatic disease, both progressing after at least 6 months of hormonal therapy for ER+ breast cancer
Women (?18 years of age) with metastatic breast cancer not amenable to curative treatment by surgery or radiotherapy.
Nasopharyngeal carcinoma basket\r\n* Metastatic or locally recurrent disease not amenable to curative intent treatment\r\n* Any number of prior therapies, including 0
Merkel cell carcinoma basket \r\n* Metastatic or locally recurrent disease not amenable to curative intent treatment\r\n* Any number of prior therapies, including 0
Pleural mesothelioma basket\r\n* Metastatic or locally recurrent disease not amenable to curative intent treatment\r\n* Refractory to platinum and pemetrexed systemic therapy\r\n* Any number of prior therapies
Histologically or cytologically confirmed breast cancer with evidence of metastatic or locally advanced disease not amenable to resection or radiation therapy with curative intent and who have progressed during treatment with at least one prior hormonal therapy
Newly diagnosed locally advanced tumour which requires upfront systemic chemotherapy but is still amenable to curative treatment (i.e. chemotherapy followed by definitive chemoradiotherapy)
Locally recurrent tumor which is amenable to curative resection (as deemed by a local surgeon or multidisciplinary team)
Patient has advanced (loco regionally recurrent not amenable to curative therapy, e.g. surgery and/or radiotherapy, or metastatic) breast cancer. Patients may be:
Adult Asian women with locoregionally recurrent or metastatic disease not amenable to curative therapy
Patient has advanced (locoregionally recurrent or metastatic) breast cancer not amenable to curative therapy
Have locoregionally recurrent disease not amenable to resection or radiation therapy with curative intent or metastatic disease
Patients with metastatic cancer and/or cancer that is not amenable to surgery (i.e. must be curative intent; locally advanced is acceptable)
Histologically documented triple-negative adenocarcinoma of the breast that is inoperable locally advanced or metastatic and is not amenable to resection with curative intent
Any previous therapy, including chemotherapy or hormonal or targeted therapy, for inoperable locally advanced or metastatic triple-negative adenocarcinoma of the breast. Participants may have received prior neoadjuvant or adjuvant chemotherapy and/or radiation treatment for locally advanced triple negative adenocarcinoma, provided all treatments were completed greater than or equal to (>/=) 6 months prior to Cycle 1 Day 1. Locally recurrent disease must not be amenable to resection with curative intent
Histologically or cytologically proven diagnosis of adenocarcinoma of the breast with evidence of locally recurrent disease not amenable to resection or radiation therapy with curative intent, or metastatic disease.
Women 18 years or older with metastatic or locally advanced disease, not amenable to curative therapy
Metastatic or locally advanced disease that is not amenable to resection or radiation with curative intent.
Adult women with locoregionally recurrent or metastatic disease not amenable to curative therapy.
Patients must have histological or cytological diagnosis of melanoma with progressive locally advanced or metastatic disease that is not amenable to definitive local therapy with curative intent
Locally advanced/metastatic NSCLC, not amenable to curative surgery or radiotherapy
Locally advanced or metastatic NSCLC, not amenable to curative surgery or radiotherapy.
Advanced (not amenable to curative surgery or radiation therapy) or metastatic (AJCC Stage IV) RCC
Have locally advanced disease not amenable to curative treatment by surgery or metastatic disease. In addition, participants must fulfill 1 of the following criteria:
Subject must have advanced or metastatic squamous NSCLC that is not amenable to surgical resection or radiation with curative intent at time of study Screening.
Histologically confirmed recurrent or metastatic SCCHN (oral cavity, pharynx, larynx), stage III/IV and not amenable to local therapy with curative intent (surgery or radiation therapy with or without chemotherapy)
Women with advanced (locoregionally recurrent or metastatic) breast cancer not amenable to curative therapy.
Histological diagnosis of locally advanced (primary or recurrent) or metastatic solid tumors that are not amenable for treatment with curative intent in adult patients with: NSCLC, TNBC, HR+ breast cancer, recurrent platinum sensitive ovarian cancer, UC, CRPC, and other advanced solid tumors with a BRCA or ATM gene defect
Histologically and cytologically proven locally advanced or metastatic pancreatic adenocarcinoma that is not amenable to surgery, radiation, or combined modality therapy with curative intent, and has failed or is not eligible for available chemotherapies
Disease which is amenable to curative local therapy
PK expansion patients: Histologic documentation of locally unresectable or metastatic renal cell carcinoma not currently amenable to surgery, radiation, or other therapy with curative intent
Patients with metastatic or locally advanced, unresectable breast cancer not amenable to curative treatment by surgery or radiotherapy
Subjects must have metastatic and/or locally advanced or locally recurrent disease that is not amenable to curative surgical resection; If a patient declines surgery, they may be considered for this study
Locally recurrent disease must not be amenable to surgical resection or radiation with curative intent.
Histologically-confirmed MBC not deemed amenable to curative surgery or curative radiation therapy
Metastatic disease not amenable to surgical resection with curative intent
Patients must have documented locally advanced/metastatic disease, defined by the investigator, which is not amenable to resection with curative intent.
Recurrent or metastatic disease that is not amenable to therapy with curative intent (surgery or radiation therapy with or without chemotherapy)
Subject has histologically confirmed locally advanced or unresectable Stage IIIB (not amenable to receive curative treatments such as chemo-radiation)/IV or metastatic NSCLC.
Histological or cytological diagnosis of triple negative breast cancer (TNBC) with evidence of a) metastatic or b) locally recurrent advanced disease that is not amenable to resection or radiotherapy with curative intent.
Patients with carcinoma of the cervix must have advanced disease not amenable to curative surgery and/or radiation therapy
Disease that is currently not amenable to curative surgical intervention.
Females with a histologically confirmed diagnosis of breast cancer that is metastatic or locally advanced (locally advanced tumors must not be amenable to surgery or radiation therapy with curative intent) with the following pathological characteristics determined locally: estrogen receptor positive and Human Epidermal Growth Factor Receptor 2 (HER-2) negative, and Ki67 (a tumor marker) ? 15% determined by the central study laboratory
Have evidence of persistent, recurrent, or progressive disease for which there is no known or established treatment available with curative intent, after at least one course of systemic therapy for locally advanced or metastatic disease , including chemotherapy, targeted therapy (small molecule or antibody based), or hormonal therapy
Metastatic or locally advanced disease not amenable to curative surgery and/or radiotherapy
Women or men aged =>18 years with histologically documented triple-negative breast cancer (TNBC) or HR+/HER2- adenocarcinoma of the breast that is locally advanced or metastatic and is not amenable to resection with curative intent
Locally advanced or metastatic disease; locally advanced disease must not be amenable to resection with curative intent.
Must have recurrent or metastatic disease that is not amenable to therapy with curative intent (surgery and/or radiation therapy with or without chemotherapy).
Measurable disease that is amenable to curative intent therapy, or amenable to standard of care systemic/palliative therapy (e.g. platinum containing chemotherapy, cetuximab, pembrolizumab or other approved options)
Patients with metastatic and/or advanced solid tumors or lymphomas not amenable to curative treatment by surgery.
The participant has disease that is not amenable to a curative approach
Women (?18 years of age) with metastatic breast cancer not amenable to curative treatment by surgery or radiotherapy.
Adult women > 18 years of age with metastatic or locally advanced breast cancer not amenable to curative treatment by surgery or radiotherapy
Has locally advanced or metastatic NSCLC, not amenable to curative surgery or radiation
Locally advanced or metastatic disease; locally advanced disease must not be amenable to resection with curative intent.
Histologically confirmed recurrent or metastatic HNSCC (oral cavity, pharynx, or larynx) that is stage III/IV and not amenable to local therapy with curative intent (surgery or radiation therapy with or without chemotherapy).
Prior treatment with >1 line of chemotherapy for metastatic breast cancer or for locoregional recurrence that was not amenable to resection or radiation therapy with curative intent.
Experienced PD on >2 endocrine therapies for metastatic breast cancer or for locoregional recurrence that was not amenable to resection or radiation therapy with curative intent.
Locally advanced or metastatic disease; locally advanced disease must not be amenable to resection with curative intent
